[1] POLAND GA,JACOBSON RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine[J]. N Engl J Med,2004,351(27):2832-2838. [2] 刘晓燕,胡瑾华,王慧芬,等. 1977例急性、亚急性、慢加急性肝衰竭患者的病因与转归分析[J]. 中华肝脏病杂志,2008,16(10):772-775. [3] TSANG SW,CHAN HL,LEUNG NW,et al. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection[J]. Aliment Pharmacol Ther,2001,15(11):1737-1744. [4] 中华医学会感染病学会分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊疗指南[J].实用肝脏病杂志,2006,9:321-324. [5] APASL consensus on ACLF//Final Recommendations of APASL Live.Data Share and Consensus Development Meeting on Acute on Chronic Liver Failure(ACLF). New Demi.[2008-01-22].http://www.aclf.in/ downloads. html. [6] IANNACONE M,SITIA G,RUGGED ZM,et a1.HBV pathogenesis in animai models:recent advances on the role of platelets[J].J Hepatol,2007,46:719-726. [7] LEIFELD L,NATTERMANN J,FIELENBACH M,et a1.Intrahepatic antivafion of caspascs in human fulminant hepatic failure[J].Liver Int,2006,26(7):872-879. [8] CHEN CH,HUNG CH,LEE CM,et a1.Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients[J]. Gastroenterology,2007,133(5):1466-1474. [9] PETERS MG,HARM HW,MARTIN P,et a1.Adefovir dipivoxil done or in combination with eamimdine in patients witlI lamivudine-resistant chronic hepatitis B[J].Gastroenterology,2004,126(1):91-101. [10] HOU J,YIN YK,XU D,et al. Telbivudine versus lamivudine in Chinese patient swith chronic hepatitis B: Results at 1 year of a randomized,double-blind trial[J]. Hepatology,2008,47(2):447-454. [11] LAI CL,GANE E,LIAW YF,et al.Globe Study Group[J]. N Engl J Med,2007,357(25):2576-2588. [12] LAI CL,GANE E,THONGSAWAT S,et al. Telbivudine(LdT)vs. Lamivudine in the treatment of Chronic Hepatitis B:Results from GLOBE,an international Phase Ⅲ Trial[R]. Shanghai-HongKong International Liver Congress,2006:Poster 182. [13] LEUNG N,GISH RG,WANG C,et al. A randomized,double-blind comparison of 3 doses of emtricitabine in patients with chronic hepatitis B given 48 weeks of treatment[J]. Hepatology,2001,34(suppl 1):349A. [14] PETERS MG,HANN HW H,MARLIN P,et a1.Adefovirdipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B[J]. Gastroenterology,2004,126(1):91-101. [15] INNAIMO SF,SEIFER M,BISACCHI GS,et al. Identification of BMS-200475 as potent and selective inhibitor of hepatitis B virus[J]. Antimicrob Agents Chemother,1997,41(7):1444-1448. [16] YAO GB.Entecavir is a potent anti-HBV drug superior to lamivudine:experience from clinical trials in China[J]. J Antimicrob Chemother,2007,60(2):201-205. [17] YAO GB,CHEN CW,LU WL,et al. Virologic,serologic,and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive chinese patients with chronic hepatitis B:a randomized,multicenter study[J]. Hepatol Int,2008,2(4):486-493. [18] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL Clinical Practice Guidelines:Management of chronic hepatitis B[J]. J Hepatol,2009,50(2):227-242. [19] VAN B?觟MMEL F,DE MAN RA,STEIN K,et al. A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBVmonoinfected patients with prior nucleos(t)ide analog experience[J]. J Hepatol,2008,48(suppl 2):S32. [20] MENNE S,COTE PJ,KORBA BE,et al. Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection[J]. Antimicrob Agents Chemother,2005,49(7):2720-2728. [21] LOK ASF,MCMAHON BJ.AASLD Practice Guideline Chronic Hepatitis B:Update of recommendations[J]. Hepatology,2004,39(3):857-861. [22] TILLMANN HL,HADEM J,LEIFELD L,et al. Safety and efficacy of lamivudine in patientswith severe acute or fulminant hepatitisB,amulticenter experience[J]. J Viral Hepat,2006,13(4):256-263. [23] JOCHUM C,GIESELER RK,GAWLISTA I,et al. Hepatitis B-associated acute liver failure:Immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae[J]. Digestion,2009,80(4):235-240. [24] 朱爱红,丁苇. 恩替卡韦治疗慢加急性肝衰竭的临床观察[J]. 齐齐哈尔医学院学报,2009,30(14):1690-1691. [25] 孙丽杰,于建武,赵勇华,等. 影响拉米夫定治疗乙型肝炎慢加急性肝衰竭预后的因素分析[J]. 中华内科杂志,2009,48(2):149-150. [26] 肖光明,贾卫东,何凯茵,等. 应用Cox 比例风险模型分析抗病毒治疗对慢性乙型重型肝炎预后的影响[J]. 实用肝脏病杂志,2009,12(3):190-194. [27] CHIEN RN,LIN CH,LIAW YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B[J]. J Hepatol,2003,38(3):322-327. [28] YUEN MF,SABLON E,HUI CK,et al. Prognostic factors in severe exacerbation of chronic hepatitis B[J].CD,2003,36(8):978-984. [29] CHEN J,HAN JH,LIU C,et al. Short-term entecavir therapy of chronic severe hepatitis B[J]. Hepatobiliary Pancreat Dis Int,2009,8(3):261-266. [30] 刘晓燕,胡瑾华,王慧芬. 乙型肝炎病毒感染所致慢加急性肝衰竭的临床预后分析[J]. 中华肝脏病杂志,2009,17(8):607-610. |